Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2017
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Gilead Sciences | National Institute of Diabetes and Digestive and Kidney Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Harvoni Treatment Porphyria Cutanea Tarda
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Porphyria Cutanea Tarda.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2017
Lead Product(s) : Ledipasvir
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Gilead Sciences | National Institute of Diabetes and Digestive and Kidney Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2017
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2016
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 07, 2016
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2016
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2016
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Gilead Sciences | University of Nebraska
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Hepatitis C Treatment During Pregnancy
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2016
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Gilead Sciences | University of Nebraska
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2015
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ledipasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2015
Lead Product(s) : Ledipasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
